Personalis (NASDAQ:PSNL) Earns Buy Rating from HC Wainwright

Personalis (NASDAQ:PSNL - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $11.00 target price on the stock. HC Wainwright's price objective suggests a potential upside of 96.43% from the stock's current price.

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $7.25 target price on shares of Personalis in a research note on Friday, December 20th.

Personalis Price Performance

NASDAQ PSNL traded down $0.38 during trading on Wednesday, hitting $5.60. 1,703,489 shares of the company's stock traded hands, compared to its average volume of 1,113,378. The stock has a fifty day moving average of $4.69 and a two-hundred day moving average of $4.32. Personalis has a 12-month low of $1.12 and a 12-month high of $7.20. The firm has a market cap of $395.63 million, a P/E ratio of -3.33 and a beta of 1.75.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The company had revenue of $25.71 million for the quarter, compared to analysts' expectations of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same quarter in the prior year, the company earned ($0.51) earnings per share. As a group, analysts expect that Personalis will post -1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

Large investors have recently made changes to their positions in the business. nVerses Capital LLC bought a new stake in Personalis in the third quarter valued at $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of Personalis by 42.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock valued at $81,000 after purchasing an additional 4,504 shares in the last quarter. International Assets Investment Management LLC boosted its stake in shares of Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company's stock valued at $113,000 after purchasing an additional 17,082 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Personalis during the third quarter valued at about $210,000. Finally, Barclays PLC raised its stake in Personalis by 45.4% in the third quarter. Barclays PLC now owns 65,468 shares of the company's stock worth $352,000 after buying an additional 20,444 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.